FDA Updates Plavix Labeling to Warn Against Co-Administration with Other CYP2C19 Inhibitors

This week's labeling change follows an earlier update from the agency informing healthcare providers of studies indicating poor CYP2C19 metabolizers have limited response to Plavix.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.